Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Official comments .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

JANUARY 10, 2023

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. . The post Breakthrough Therapy designation for pneumococcal disease vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Therapies Disease Immune Response 130

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” .

Vaccine 148

Vaccine Clinical Trials FDA Approval Research Laboratories 148

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccine 265

Vaccine Virus Medical Schools Immune Response 265

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccine 130

Vaccine Clinical Trials Trials Disease 130

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. The day aims to raise awareness about the devastating health, social, and economic consequences of the disease.

Vaccine 130

Vaccine Clinical Trials Licensing Licensing 130

Drug Discovery World

JANUARY 16, 2024

A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB.

Clinical Trials 148

Clinical Trials Vaccine Trials Immune Response 148

Drug Discovery World

FEBRUARY 14, 2024

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Vaccine 148

Vaccine Production Virus DNA 148

Drug Discovery World

JANUARY 16, 2024

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH.

Vaccine 163

Vaccine Disease Research Drugs 163

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drug Discovery World

APRIL 13, 2023

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. The vaccine has been approved for use in children aged five to 36 months, the age group at highest risk of death from malaria.

Vaccine 246

Vaccine Clinical Trials Trials Production 246

Drug Discovery World

MARCH 13, 2024

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86. strains after their booster vaccination.

Vaccine 130

Vaccine Research Virus Hospitals 130

Drug Discovery World

NOVEMBER 2, 2023

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups.

Vaccine 130

Vaccine FDA Approval FDA Disease 130

Drug Discovery World

JANUARY 8, 2024

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS).

Vaccine 148

Vaccine Clinical Trials Licensing Licensing 148

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). The post Study suggests ways to improve future HIV vaccine candidates appeared first on Drug Discovery World (DDW).

Vaccine 148

Vaccine Clinical Trials Laboratories Virus 148

Drug Discovery World

JANUARY 12, 2024

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments. Knowledge gained could also inform development of other Paramyxovirus countermeasures.”

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

MARCH 15, 2024

Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 148

Vaccine Science Clinical Trials Virus 148

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

PPD

JUNE 24, 2024

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. We look forward to working with our colleagues at Moderna to advance mRNA-4157/V940 in combination with KEYTRUDA as it aligns with our strategy to impact early-stage disease.”.

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. A next-generation rabies vaccine with improved immunogenicity and simpler manufacturing represents an opportunity to establish wider accessibility to rabies prevention worldwide.

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

AUGUST 25, 2023

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). In 2022, Schulz’s team also found that people who received at least one influenza vaccine were 40% less likely than their unvaccinated peers to develop AD.

Vaccine 130

Vaccine Medical Schools Immune Response Disease 130

SCIENMAG: Medicine & Health

JULY 30, 2023

Research Highlights: A novel vaccine that targets a protein involved in Alzheimer’s disease helped eliminate toxic cells in mice with the condition. After vaccination, the mice had fewer amyloid plaques and less inflammation in brain tissue and showed improvement in behavior and awareness. Embargoed until 12 p.m.

Vaccine 96

Vaccine Disease Research 96

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccine 130

Vaccine Trials Animal Testing Virus 130

Drug Discovery World

JUNE 6, 2023

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. A vaccine to help prevent RSV had been an elusive public health goal for more than half a century.

FDA Approval 130

FDA Approval Virus Vaccine FDA 130

Drug Discovery World

FEBRUARY 22, 2023

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding. Dr David Milan, Leducq Chief Scientific Officer, said this innovative approach to a Strep A vaccine fell squarely within the cardiovascular disease mission of the Leducq Foundation.

Vaccine 130

Vaccine Research Disease Drugs 130

Drug Discovery World

OCTOBER 3, 2023

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.

Vaccine 148

Vaccine Clinical Trials Licensing Licensing 148

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

OCTOBER 31, 2023

The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. As we age, our immune system changes and with it our response to vaccines.

Vaccine 130

Vaccine Immune Response Disease Research 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 148

Disease Research RNA Therapies 148

Drug Discovery World

APRIL 24, 2023

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. There is currently no vaccine available. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide.

Vaccine 130

Vaccine Trials Clinical Trials Disease 130

Drug Discovery World

AUGUST 9, 2023

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect infants and toddlers from RSV.

Vaccine 130

Vaccine Virus Disease Drugs 130

Drug Discovery World

FEBRUARY 22, 2023

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

Vaccine 130

Vaccine Trials FDA Disease 130

Drug Discovery World

NOVEMBER 4, 2022

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. However, their previously identified correlates of risk of TB disease were not associated with an increased risk of M.tb

Vaccine 130

Vaccine Immune Response Disease Research 130

Drug Discovery World

MARCH 24, 2023

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

Vaccine 130

Vaccine Virus Disease Drugs 130